Robert C. Kill Joins Accuray Board of Directors

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) appointed Robert C. Kill to its Board of Directors, effective January 30, 2023. With over 30 years of experience in healthcare, Kill's previous role as CEO of Parata Systems saw revenue growth exceeding 5X before its sale for over $1.5 billion. His expertise in transforming healthcare companies aligns with Accuray’s strategic focus. Suzanne Winter, President and CEO, expressed enthusiasm about Kill's addition, highlighting his reputation for generating positive business outcomes. Kill aims to leverage Accuray’s radiation therapy technology to unlock its untapped potential.

Positive

• Appointment of Robert C. Kill brings extensive healthcare experience.
• Previous CEO of Parata Systems with revenue growth over 5X.
• Potential for enhanced strategic direction with Kill's leadership.

Negative

• None.

SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies.

In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazier Healthcare Partners and Altamont Capital Partners, where he focused on various health care portfolio companies. Prior to this, Mr. Kill held executive leadership positions with medical device, healthcare service and healthcare IT companies. He began his career at Baxter Healthcare.  

"Rob's public and private company CEO experiences directly align with our organization's strategic focus areas, making him an excellent addition to the Accuray Board of Directors. He has a well-established reputation for driving transformative business results, improving customers' experience and managing key stakeholder relationships on behalf of both large and small companies. We are very excited to have Rob join our board and look forward to his contributions," said Suzanne Winter, President and CEO of Accuray.

"As a healthcare industry veteran, I understand the value that the Accuray radiation therapy technology provides to medical care teams and patients, and I strongly believe there is untapped potential here. I'm looking forward to working with Suzanne, the senior management team and other board members to help create value for all of Accuray's constituents," said Rob Kill.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Investor Contact	Media Contact
Aman Patel,CFA	Beth Kaplan
Investor Relations, ICR-Westwicke	Accuray
+1 (443) 450-4191	+1 (408) 789-4426
amanpatel@westwicke.com	bkaplan@accuray.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-c-kill-joins-accuray-board-of-directors-301735852.html

SOURCE Accuray Incorporated

FAQ

Who is Robert C. Kill and what is his role at Accuray?

Robert C. Kill is a healthcare executive appointed to Accuray's Board of Directors effective January 30, 2023.

What was Robert C. Kill's previous achievement before joining Accuray?

He was the CEO of Parata Systems, where he grew revenue over 5 times before the company was sold for more than $1.5 billion.

What is the significance of Robert C. Kill's appointment for ARAY investors?

Kill's extensive experience in healthcare may drive transformative business results, potentially increasing shareholder value.